vs
Maase Inc.（MAAS）与Sol-Gel Technologies Ltd.（SLGL）财务数据对比。点击上方公司名可切换其他公司
Sol-Gel Technologies Ltd.的季度营收约是Maase Inc.的1.7倍（$17.3M vs $9.9M）
Sol-Gel Technologies Ltd.是一家专注皮肤科药物研发的专业生物制药企业，依托专有溶胶凝胶递送技术开发痤疮、玫瑰痤疮、特应性皮炎等常见皮肤疾病的外用治疗方案，核心市场覆盖北美与欧洲，与医疗行业知名企业合作推进产品商业化。
MAAS vs SLGL — 直观对比
营收规模更大
SLGL
是对方的1.7倍
$9.9M
损益表 — Q2 FY2023 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9M | $17.3M |
| 净利润 | — | $11.6M |
| 毛利率 | 78.7% | — |
| 营业利润率 | -55.9% | 65.1% |
| 净利率 | — | 67.3% |
| 营收同比 | — | 217.7% |
| 净利润同比 | — | 487.6% |
| 每股收益（稀释后） | — | $4.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MAASSLGL
| Q2 25 | — | $17.3M | ||
| Q2 24 | — | $5.4M | ||
| Q2 23 | — | $594.0K | ||
| Q4 22 | $9.9M | — | ||
| Q2 22 | — | $3.5M |
净利润MAASSLGL
| Q2 25 | — | $11.6M | ||
| Q2 24 | — | $2.0M | ||
| Q2 23 | — | $-6.0M | ||
| Q4 22 | — | — | ||
| Q2 22 | — | $-134.0K |
毛利率MAASSLGL
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | 78.7% | — | ||
| Q2 22 | — | — |
营业利润率MAASSLGL
| Q2 25 | — | 65.1% | ||
| Q2 24 | — | 29.9% | ||
| Q2 23 | — | -1098.8% | ||
| Q4 22 | -55.9% | — | ||
| Q2 22 | — | -13.2% |
净利率MAASSLGL
| Q2 25 | — | 67.3% | ||
| Q2 24 | — | 36.4% | ||
| Q2 23 | — | -1005.1% | ||
| Q4 22 | — | — | ||
| Q2 22 | — | -3.8% |
每股收益（稀释后）MAASSLGL
| Q2 25 | — | $4.17 | ||
| Q2 24 | — | $0.71 | ||
| Q2 23 | — | $-0.22 | ||
| Q4 22 | — | — | ||
| Q2 22 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.9M | $24.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $31.6M | $31.9M |
| 总资产 | $47.0M | $39.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MAASSLGL
| Q2 25 | — | $24.3M | ||
| Q2 24 | — | $26.5M | ||
| Q2 23 | — | $33.5M | ||
| Q4 22 | $10.9M | — | ||
| Q2 22 | — | $15.6M |
股东权益MAASSLGL
| Q2 25 | — | $31.9M | ||
| Q2 24 | — | $34.9M | ||
| Q2 23 | — | $48.3M | ||
| Q4 22 | $31.6M | — | ||
| Q2 22 | — | $50.4M |
总资产MAASSLGL
| Q2 25 | — | $39.3M | ||
| Q2 24 | — | $42.0M | ||
| Q2 23 | — | $55.1M | ||
| Q4 22 | $47.0M | — | ||
| Q2 22 | — | $55.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-18.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-18.3M | — |
| 自由现金流率自由现金流/营收 | -184.4% | — |
| 资本支出强度资本支出/营收 | 1.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MAASSLGL
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | $-8.3M | ||
| Q4 22 | $-18.2M | — | ||
| Q2 22 | — | — |
自由现金流MAASSLGL
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | $-8.4M | ||
| Q4 22 | $-18.3M | — | ||
| Q2 22 | — | — |
自由现金流率MAASSLGL
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | -1419.0% | ||
| Q4 22 | -184.4% | — | ||
| Q2 22 | — | — |
资本支出强度MAASSLGL
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | 15.8% | ||
| Q4 22 | 1.0% | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
SLGL
暂无分部数据
